Phase 2 Study of Novel Partial Tumor Irradiation for Sparing Peri-Tumoral Immune Microenvironment.

被引：0
|
作者：
Tubin, S. [1 ]
Khan, M. K. [2 ]
Salerno, G. [3 ]
Mourad, W. F. [4 ]
Yan, W. [5 ]
Jeremic, B. [6 ,7 ,8 ]
机构：
[1] Landeskrankenhaus Klagenfurt, Strahlentherapie & Radioonkol, Klagenfurt, Austria
[2] Emory Univ, Sch Med, Winship Canc Ctr, Dept Radiat Oncol, Atlanta, GA 30322 USA
[3] Univ Roma La Sapienza, Osped St Andrea, Dept Neurosci Mental Hlth & Sensory Organs, Dept Clin & Mol Med, Rome, RM, Italy
[4] Univ Kentucky, Dept Radiat Med, Markey Canc Ctr, Lexington, KY USA
[5] Thomas Jefferson Univ Philadelphia, Dept Radiat Oncol, Philadelphia, PA USA
[6] Res Inst Clin Med, Tbilisi, Georgia
[7] BioIRC R&D Ctr Biomed Res, Kragujevac, Serbia
[8] Dept Radiat Oncol, Tbilisi, Georgia
来源：
RADIOTHERAPY AND ONCOLOGY | 2020年 / 152卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PH-0282
引用
收藏
页码：S142 / S143
页数：2
相关论文
共 50 条
  • [31] Multicenter Phase 2 Study of Concurrent Chemoradiation Therapy Plus Peri-Irradiation Chemotherapy for Inoperable Nonmetastatic Gastric Cancer
    Chen, T.
    Liu, Y.
    Guoqi, Z.
    Xu, Y.
    He, X.
    Li, X.
    Chen, H.
    Yao, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S30 - S30
  • [32] Phase II study in pediatric and AYA patients with non-metastatic high-grade extremity osteosarcoma with a risk-adapted strategy based on P-glycoprotein (ISG/OS-2): A correlative study on tumour immune microenvironment.
    Palmerini, Emanuela
    Sapienza, Maria Rosaria
    Pileri, Stefano A.
    Righi, Alberto
    Parafioriti, Antonina
    Franchi, Alessandro
    Agostinelli, Claudio
    Meazza, Cristina
    Ferraresi, Virginia
    Asaftei, Sebastian Dorin
    Coccoli, Luca
    Tamburini, Angela
    Gambarotti, Marco
    Serra, Massimo
    Donati, Davide Maria
    Fagioli, Franca
    Cesari, Marilena
    Scotlandi, Katia
    Laginestra, Maria Antonella
    Ibrahim, Toni
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] TARGETING FPR2 AS A NOVEL APPROACH FOR IMMUNOTHERAPY IN PANCREATIC CANCER FEMALE PATIENTS - STUDIES OF SEXUAL IMMUNE DIMORPHISM IN THE TUMOR MICROENVIRONMENT
    Sarhan, Dhifaf
    He, Fei
    Calandigary, Ahmed
    Malki, Enana
    Moro, Carlos Fernandez
    Kaisso, Marina
    Olofsson-Sahl, Peter
    Melssen, Marit
    Lohr, Matthias
    Karlsson, Mikael
    Heuchel, Rainer
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A927 - A927
  • [34] Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia
    Newland, Adrian C.
    Sanchez-Gonzalez, Blanca
    Rejto, Laszlo
    Egyed, Miklos
    Romanyuk, Nataliya
    Godar, Marie
    Verschueren, Katrien
    Gandini, Domenica
    Ulrichts, Peter
    Beauchamp, Jon
    Dreier, Torsten
    Ward, E. Sally
    Michel, Marc
    Liebman, Howard A.
    De Haard, Hans
    Leupin, Nicolas
    Kuter, David J.
    BLOOD, 2019, 134
  • [35] Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia
    Newland, Adrian C.
    Sanchez-Gonzalez, Blanca
    Rejto, Laszlo
    Egyed, Miklos
    Romanyuk, Nataliya
    Godar, Marie
    Verschueren, Katrien
    Gandini, Domenica
    Ulrichts, Peter
    Beauchamp, Jon
    Dreier, Torsten
    Ward, E. Sally
    Michel, Marc
    Liebman, Howard A.
    de Haard, Hans
    Leupin, Nicolas
    Kuter, David J.
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (02) : 178 - 187
  • [36] A Phase 2 Study of Hypofractionated Partial Breast Irradiation (HF-PBI) in Women with Early Stage Breast Cancer
    Fang, P.
    Bloom, E.
    Woodward, W. A.
    Stauder, M. C.
    Tereffe, W.
    Chun, S. G.
    Schlembach, P. J.
    Mayo, L. L.
    Ahmad, N. R.
    Arzu, I. Y.
    Reed, V. K.
    Chronowski, G. M.
    Delclos, M. E.
    Smith, B. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E584 - E585
  • [37] Intratumoral coxsackievirus A21 increases immune-cell infiltrates and upregulates immune-checkpoint molecules in the tumor microenvironment of advanced melanoma patients: phase II CALM extension study
    Andtbacka, Robert
    Curti, Brendan
    Hallmeyer, Sigrun
    Peng, Zipei
    Paustian, Christopher
    Bifulco, Carlo
    Fox, Bernard
    Grose, Mark
    Shafren, Darren R.
    CANCER RESEARCH, 2016, 76
  • [38] Comprehensive evaluation of the tumor immune microenvironment and its dynamic changes in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy: From the phase II ADORE study
    Cho, Hyungwoo
    Kim, Jeong Eun
    Hong, Yong Sang
    Kim, Sun Young
    Kim, Jihun
    Ryu, Yeon-Mi
    Kim, Sang-Yeob
    Kim, Tae Won
    ONCOIMMUNOLOGY, 2022, 11 (01):
  • [39] RETRACTED: GNAI2 Is a Risk Factor for Gastric Cancer: Study of Tumor Microenvironment (TME) and Establishment of Immune Risk Score (IRS) (Retracted Article)
    Yu, Han
    Liu, Sha
    Wu, ZuGuang
    Gao, FenFei
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2022, 2022
  • [40] ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment
    Ponce, Santiago
    Cedres, Susana
    Ricordel, Charles
    Isambert, Nicolas
    Viteri, Santiago
    Herrera-Juarez, Mercedes
    Martinez-Marti, Alex
    Navarro, Alejandro
    Lederlin, Mathieu
    Serres, Xavier
    Zugazagoitia, Jon
    Vetrhus, Sylvia
    Jaderberg, Magnus
    Hansen, Thomas Birkballe
    Levitsky, Victor
    Paz-Ares, Luis
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (09)
12345